23 March 2015, 7:20 am
Good mental health was the only significant factor associated with optimal pill-taking among people taking antiretroviral therapy (ART) for the prevention of sexual transmission of HIV, investigators from the HPTN 052 study report in the online edition of the Journal of Acquired Immune Deficiency Syndromes. High levels of adherence were observed after one month

20 March 2015, 10:20 am
A Canadian paper that weighs the cost of using pre-exposure prophylaxis (PrEP) to prevent HIV infections against the lifetime total cost of one HIV infection finds that, using figures available for Quebec and Ontario provinces, PrEP would be cost-saving under most scenarios, even if the overall lifetime cost of HIV care falls in the

19 March 2015, 8:50 am
An combination of two once-daily oral antiretrovirals – the next-generation integrase inhibitor cabotegravir (GSK1265744) and the approved NNRTI rilpivirine (Edurant, also in Eviplera or Complera) – was as effective as an efavirenz (Sustiva)-based regimen when used as maintenance therapy to keep viral load suppressed, according to a poster presented at the recent Conference on Retroviruses and Opportunistic

18 March 2015, 10:30 am
The Fracture Risk Assessment Tool (FRAX), an online tool developed by the World Health Organization and used to help guide decisions about who to screen or treat in order to prevent bone fractures, underestimates overall risk of fracture in people living with HIV – even with an adjustment experts have recommended to improve its

17 March 2015, 9:50 am
Almost all patients with hepatitis C virus (HCV) alone or HIV and HCV co-infection who achieved sustained virological response (SVR) to treatment with sofosbuvir (Sovaldi) plus ribavirin or sofosbuvir/ledipasvir (Harvoni) still had undetectable HCV RNA up to two years later, confirming that SVR represents a cure, according to a poster presented at the recent

1 2

    • No upcoming events
  • View All Add your news